Thalamic and hypothalamic tumors of childhood: endocrine late effects.
Children who have received chemotherapy and radiation therapy for treatment of thalamic/hypothalamic tumors are at risk for late effects, specifically endocrine dysfunction. Evaluation of growth and pubertal development, thyroid function and integrity of the hypothalamic-pituitary-adrenal axis should be undertaken in a prospective manner. Issues of metabolic disturbances such as obesity, altered body composition/bone density as well as ultimate fertility also need to be addressed by ongoing prospective evaluations.
Oberfield
S E
SE
Division of Pediatric Endocrinology and Pediatric Oncology, Babies and Children's Hospital of New York, NY 10032, USA. seo8@columbia.edu
Garvin
J H
JH
D000293:Adolescent; D000309:Adrenal Insufficiency / Q000209:etiology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001827:Body Height / Q000528:radiation effects; D002648:Child; D002675:Child, Preschool; D004307:Dose-Response Relationship, Radiation; D004700:Endocrine System Diseases / Q000209:etiology*; D005260:Female; D006130:Growth Disorders / Q000209:etiology; D013006:Growth Hormone / Q000172:deficiency; D020249:Hormone Replacement Therapy; D006801:Humans; D006949:Hyperlipidemias / Q000209:etiology; D007029:Hypothalamic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D007037:Hypothyroidism / Q000209:etiology; D007223:Infant; D008297:Male; D011629:Puberty, Precocious / Q000209:etiology; D011832:Radiation Injuries / Q000209:etiology*; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D015173:Supratentorial Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000532:radiotherapy*
D013006:Growth Hormone